Fujita K, Munakata A
Department of Urology, National Medical Center, Tokyo, Japan.
Int J Clin Pharmacol Res. 1991;11(4):171-4.
The concentrations of 5-fluorouracil (5-FU) and related compounds were studied in tissues including renal cells removed from 27 cancer patients, to whom UFT (a mixture of uracil and tegafur in a molecular ratio of 4:1) was administered orally over 5 days. The level of 5-FU in cancer tissue was two-fold that of the normal kidney (87 +/- 79 ng/g vs. 38 +/- 29 ng/g, p less than 0.005), with almost the same level of tegafur. The serum 5-FU level was as low as 4 ng/ml. These results confirm the high efficiency of UFT with minimal side-effects compared to tegafur.
对27例癌症患者口服优福定（尿嘧啶与替加氟分子比为4:1的混合物）5天，研究了从这些患者身上获取的包括肾细胞在内的组织中5-氟尿嘧啶（5-FU）及相关化合物的浓度。癌组织中5-FU水平是正常肾组织的两倍（87±79 ng/g对38±29 ng/g，p<0.005），替加氟水平几乎相同。血清5-FU水平低至4 ng/ml。这些结果证实了优福定相较于替加氟具有高效且副作用小的特点。
